Not Signed In - Somaxon Pharmaceuticals Provides Update On Preclinical And Clinical Programs For SILENOR(TM)
Tue, 12 Sep 2006 07:00 AM EST
... Somaxon Pharmaceuticals,Inc. (Nasdaq: SOMX) today announced that it has completed the genotoxicitystudies requested by the U.S. Food and Drug Administration (FDA) forSILENOR(TM) (doxepin HCl), the company's lead product candidate for thetreatment of insomnia. [click link for full article] ...
Related Topics
- Clinical Trials
- Psychopharmacology
- Pharmacology
- Clinical Growth Charts
- Patient Issues
- Walking Programs
- Fitness Programs
- Best Weight Loss Programs
- SAS Programs for Growth Charts
- Hypnotherapy
- Epidemiology
- Clinical Laboratory Improvement Amendments
- Depression
- Infectious Diseases
- Western/Clinical Treatment and Therapy
- Epidemiology & Prevention of Vaccine-Preventable Diseases
- Abstinence
- Anesthesia
- Biodefense
- Trastuzumab
email this page
print this page
bookmark this page
feedback on this page
